2.57  -0.14 (-5.17%)		12-12 15:59
Open: 2.69 High: 2.8 Volume: 53,185		Pre. Close: 2.71 Low: 2.57 Market Cap: 16(M)

Short term
Mid term
Targets	6-month :	4.82	1-year :	6.04
Resists	First :	4.13	Second :	5.17
Pivot price	2.77
Supports	First :	2.44	Second :	2.03
MAs	MA(5) :	2.76	MA(20) :	2.81
	MA(100) :	5.77	MA(250) :	0
MACD	MACD :	-0.5	Signal :	-0.6
%K %D	K(14,3) :	27.7	D(3) :	36.5
RSI	RSI(14): 35.4
52-week	High :	18.96	Low :	2.44

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ RBOT ] has closed above bottom band by 27.1%. Bollinger Bands are 67.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	2.8 - 2.83	2.83 - 2.84
Low:	2.53 - 2.55	2.55 - 2.57
Close:	2.54 - 2.58	2.58 - 2.6

Vicarious Surgical Inc. engages in developing and selling single-incision surgical robot that virtually transports surgeons inside the patient to perform minimally invasive surgery. It offers Vicarious System, a single-incision surgical robot for ventral hernia repair. The company was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Thu, 04 Dec 2025
Khalifa Sammy, Vicarious Surgical CTO, sells $709 in RBOT stock - Investing.com

Wed, 03 Dec 2025
Vicarious Surgical stock up after improved cash burn guidance - MSN

Wed, 03 Dec 2025
Vicarious Surgical (NYSE: RBOT) Trims 2025 Cash Burn by $5M, Updates Board - Stock Titan

Wed, 12 Nov 2025
Vicarious Surgical is moving surgical robot timeline back again - MassDevice

Wed, 08 Oct 2025
$5.9M Proceeds: Vicarious Surgical Prices Registered Direct Offering; 1.15M Shares to Close Oct 9 - Stock Titan

Thu, 14 Aug 2025
Vicarious Surgical's new CEO pushes back robot development timeline - Fierce Biotech

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NYSE
Sector: Healthcare
Industry: Medical - Devices
Shares Out	6 (M)
Shares Float	4 (M)
Held by Insiders	20.3 (%)
Held by Institutions	28.2 (%)
Shares Short	184 (K)
Shares Short P.Month	143 (K)

EPS	-9.03
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	2.35
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-63.4 %
Return on Equity (ttm)	-149 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-9.18
Qtrly Earnings Growth	0 %
Operating Cash Flow	-48 (M)
Levered Free Cash Flow	-28 (M)

PE Ratio	-0.29
PEG Ratio	0
Price to Book value	1.08
Price to Sales	0
Price to Cash Flow	-0.32

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.